121.48
0.61 (0.50%)
| Previous Close | 120.87 |
| Open | 121.10 |
| Volume | 329,571 |
| Avg. Volume (3M) | 716,625 |
| Market Cap | 7,109,886,976 |
| Price / Earnings (Forward) | 2.00 |
| Price / Sales | 11.12 |
| Price / Book | 9.32 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| Profit Margin | -30.57% |
| Operating Margin (TTM) | -19.39% |
| Diluted EPS (TTM) | -2.27 |
| Quarterly Revenue Growth (YOY) | 24.60% |
| Total Debt/Equity (MRQ) | 14.09% |
| Current Ratio (MRQ) | 6.49 |
| Operating Cash Flow (TTM) | -45.97 M |
| Levered Free Cash Flow (TTM) | -17.66 M |
| Return on Assets (TTM) | -6.68% |
| Return on Equity (TTM) | -20.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Glaukos Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -3.5 |
| Average | -1.13 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.33% |
| % Held by Institutions | 101.71% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HOFFMEISTER DAVID F | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HOFFMEISTER DAVID F | Director | 26 May 2026 | Option execute | 15,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |